Imipramine

Medical uses

Imipramine is primarily used for the treatment of depression and certain anxiety disorders, including acute post-traumatic stress reactions. A significant amount of research regarding its efficacy on acute post-traumatic stress in children and adolescents has focused on trauma resulting from burn-injuries. Although evidence for its efficacy in the treatment of chronic post-traumatic stress disorder appears to be less robust, it remains a viable treatment. Here, it may share a similar efficacy withe the monoamine oxidase inhibitor phenelzine.

Caution is needed in prescribing imipramine (and its commercially available metabolite, desipramine) in children and youth/adolescents (whether they suffer with, e.g., bed-wetting, recurrent panic attacks, acute trauma or, in the case of desipramine, ADHD), owing to possibility of accidental overdose, which may be of particular concern in children.

In the treatment of depression, it has demonstrated similar efficacy to the MAOI moclobemide. It has also been used to treat nocturnal enuresis because of its ability to shorten the time of delta wave stage sleep, where wetting occurs. In veterinary medicine, imipramine is used with xylazine to induce pharmacologic ejaculation in stallions. It is also used for separation anxiety in dogs and cats. Blood levels between 150 and 250 ng/mL of imipramine plus its metabolite desipramine generally correspond to antidepressant efficacy.

Contraindications

Combining it with alcohol consumption may cause more drowsiness, necessitating greater caution when drinking. It may be unsafe during pregnancy.

Many MAOIs are known to have serious interactions with imipramine. It is often contraindicated during their use or in the two weeks following their discontinuation. This category includes medications such as isocarboxazid, linezolid, methylene blue, phenelzine, selegiline, moclobemide, procarbazine, rasagiline, safinamide, and tranylcypromine.

Side effects

These side effects can be contributed to the multiple receptors that imipramine targets such as serotonin, norepinephrine, dopamine, acetylcholine, epinephrine, histamine. Those listed in italics below denote common side effects, separated by the organ systems that are affected. Some side effects may be beneficial in some cases, e.g. reduction of hyperactive gag reflex; reduced random or physical strain-linked urinary leakage.

• Central nervous system: dizziness, drowsiness, confusion, seizures, headache, anxiety, tremors, stimulation, weakness, insomnia, nightmares, extrapyramidal symptoms in geriatric patients, increased psychiatric symptoms, paresthesia
• Cardiovascular: orthostatic hypotension, ECG changes, tachycardia, hypertension, palpitations, dysrhythmias
• Eyes, ears, nose and throat: blurred vision, tinnitus, mydriasis
• Gastrointestinal: dry mouth, nausea, vomiting, paralytic ileus, increased appetite, cramps, epigastric distress, jaundice, hepatitis, stomatitis, constipation, taste change
• Genitourinary: urinary retention
• Hematological: agranulocytosis, thrombocytopenia, eosinophilia, leukopenia
• Skin: rash, urticaria, diaphoresis, pruritus, photosensitivity

Overdose

Main article: Tricyclic antidepressant#Overdose, Tricyclic antidepressant overdose

Interactions

Main article: Tricyclic antidepressant#Interactions

Like other tricyclic antidepressants, imipramine has many medication interactions. Many MAOIs have serious interactions with this medication. Other categories of medications that may interact with imipramine include blood thinners, antihistamines, muscle relaxants, sleeping pills, thyroid medications, and tranquilizers. Some medications used for various conditions such as high blood pressure, mental illness, nausea, Parkinson's disease, asthma, colds, or allergies.

Certain medications increase the risk of serotonin syndrome, including selective serotonin reuptake inhibitors (SSRIs), St. John's Wort, and drugs such as ecstasy. Other prescription drugs decrease the body's ability to eliminate imipramine. These include barbiturates, some antiarrhythmic medications, some antiepileptic drugs, and certain HIV drugs (protease inhibitors). Others may cause changes in the heart rhythm, such as QT prolongation.

Alcohol and tobacco may interact with imipramine. Tobacco may decrease the medication's effectiveness.

Pharmacology

Pharmacodynamics

Imipramine affects numerous neurotransmitter systems known to be involved in the etiology of depression, anxiety, attention-deficit hyperactivity disorder (ADHD), enuresis and numerous other mental and physical conditions. Imipramine is similar in structure to some muscle relaxants, and has a significant analgesic effect and, thus, is very useful in some pain conditions.

The mechanisms of imipramine's actions include, but are not limited to, effects on:

• Serotonin: very strong reuptake inhibition. Imipramine is a tertiary TCA, and is a potent inhibitor of serotonin reuptake, and to a greater extent than secondary amine TCAs such as nortriptyline and despiramine.
• Norepinephrine: strong reuptake inhibition. Desipramine has more affinity to norepinephrine transporter than imipramine.
• Dopamine: imipramine blocks D2 receptors. Imipramine, and its metabolite desipramine, have no appreciable affinity for the dopamine transporter (Ki = 8,500 and 10,000 nM, respectively).
• Acetylcholine: imipramine is, to a certain extent, an antimuscarinic, specifically a relative antagonist of the muscarinic acetylcholine receptors. The attendant side-effects (e.g., blurry vision, dry mouth, constipation), however, are somewhat less common with imipramine than amitriptyline and protriptyline, which tend to cause antimuscarinic side-effects more often. All-in-all, however, it is prescribed with caution to the elderly and with extreme caution to those with psychosis, as the general brain activity enhancement in combination with the "dementing" effects of anticholinergics increases the potential of imipramine to cause hallucinations, confusion and delirium in this population. "Anti-cholinergic" side-effects, including urinary hesitancy/retention, may be treated/reversed with bethanechol and/or other acetylcholine-agonists. Bethanechol may also be able to alleviate the sexual-dysfunction symptoms which may occur in the context of tricyclic-antidepressant treatment.
• Epinephrine: imipramine antagonizes adrenergic receptors, thus sometimes causing orthostatic hypotension.
• Sigma receptor: activity on sigma receptors is present, but it is very weak (Ki = 520 nM) and it is about half that of amitriptyline (Ki = 300 nM).
• Histamine: imipramine is an antagonist of the histamine H1 receptors.
• BDNF: BDNF is implicated in neurogenesis in the hippocampus, and studies suggest that depressed patients have decreased levels of BDNF and reduced hippocampal neurogenesis. It is not clear how neurogenesis restores mood, as ablation of hippocampal neurogenesis in murine models do not show anxiety related or depression related behaviours. Chronic imipramine administration results in increased histone acetylation (which is associated with transcriptional activation and decondensed chromatin) at the hippocampal BDNF promoter, and also reduced expression of hippocampal HDAC5.

Pharmacokinetics

Imipramine has a varied absolute oral bioavailability ranging from 22% to 77%, leading to significant variability in pharmacokinetics. While the drug has rapid and complete absorption after oral administration, much of the drug is affected by first pass metabolism. Food has no effect on absorption, peak drug concentration, or time to peak drug concentration.

Within the body, imipramine is converted into desipramine (desmethylimipramine) as a metabolite.

Chemistry

Imipramine is a tricyclic compound, specifically a dibenzazepine, and possesses three rings fused together with a side chain attached in its chemical structure. Other dibenzazepine TCAs include desipramine (N-desmethylimipramine), clomipramine (3-chloroimipramine), trimipramine (2′-methylimipramine or β-methylimipramine), and lofepramine (N-(4-chlorobenzoylmethyl)desipramine). Imipramine is a tertiary amine TCA, with its side chain-demethylated metabolite desipramine being a secondary amine. Other tertiary amine TCAs include amitriptyline, clomipramine, dosulepin (dothiepin), doxepin, and trimipramine. The chemical name of imipramine is 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine and its free base form has a chemical formula of C19H24N2 with a molecular weight of 280.407 g/mol. The drug is used commercially mostly as the hydrochloride salt; the embonate (pamoate) salt is used for intramuscular administration and the free base form is not used. The CAS Registry Number of the free base is 50-49-7, of the hydrochloride is 113-52-0, and of the embonate is 10075-24-8.

History

The parent compound of imipramine, 10,11-dihydro-5H-dibenz[b,f]azepine (dibenzazepine), was first synthesized in 1899, but no pharmacological assessment of this compound or any substituted derivatives was undertaken until the late 1940s. Imipramine was first synthesized in 1951, as an antihistamine. The antipsychotic effects of chlorpromazine were discovered in 1952, and imipramine was then developed and studied as an antipsychotic for use in patients with schizophrenia. The medication was tested in several hundred patients with psychosis, but showed little effectiveness. However, imipramine was serendipitously found to possess antidepressant effects in the mid-1950s following a case report of symptom improvement in a woman with severe depression who had been treated with it. This was followed by similar observations in other patients and further clinical research. Subsequently, imipramine was introduced for the treatment of depression in Europe in 1958 and in the United States in 1959. Along with the discovery and introduction of the monoamine oxidase inhibitor iproniazid as an antidepressant around the same time, imipramine resulted in the establishment of monoaminergic drugs as antidepressants.

In the late 1950s, imipramine was the first TCA to be developed (by Ciba). At the first international congress of neuropharmacology in Rome, September 1958 Dr Freyhan from the University of Pennsylvania discussed as one of the first clinicians the effects of imipramine in a group of 46 patients, most of them diagnosed as "depressive psychosis". The patients were selected for this study based on symptoms such as depressive apathy, kinetic retardation and feelings of hopelessness and despair. In 30% of all patients, he reported optimal results, and in around 20%, failure. The side effects noted were atropine-like, and most patients experienced dizziness. Imipramine was first tried for treating psychotic disorders such as schizophrenia, but proved ineffective. As an antidepressant, it did well in clinical studies and it is known to work well in even the most severe cases of depression. It is not surprising, therefore, that imipramine may cause a high rate of manic and hypomanic reactions in hospitalized patients with pre-existing bipolar disorder, with one study showing that up to 25% of such patients maintained on Imipramine switched into mania or hypomania. Such powerful antidepressant properties have made it favorable in the treatment of treatment-resistant depression.

Before the advent of selective serotonin reuptake inhibitors (SSRIs), its sometimes intolerable side-effect profile was considered more tolerable. Therefore, it became extensively used as a standard antidepressant and later served as a prototypical drug for the development of the later-released TCAs. Since SSRIs are superior in terms of inherent side-effect tolerability (although probably inferior in terms of actual efficacy), it has, as of the 1990s, no longer been used as commonly, but is sometimes still prescribed as a second-line treatment for treating major depression. It has also seen limited use in the treatment of migraines, ADHD, and post-concussive syndrome. Imipramine has additional indications for the treatment of panic attacks, chronic pain, and Kleine-Levin syndrome. In pediatric patients, it is relatively frequently used to treat pavor nocturnus and nocturnal enuresis.

Society and culture

Generic names

Imipramine is the English and French generic name of the drug and its , , and , while imipramine hydrochloride is its , , , and . Its generic name in Spanish and Italian and its are imipramina, in German is imipramin, and in Latin is imipraminum. The embonate salt is known as imipramine pamoate.

Brand names

Imipramine is marketed throughout the world mainly under the brand name Tofranil. Imipramine pamoate is marketed under the brand name Tofranil-PM for intramuscular injection.

Availability

Imipramine is available for medical use widely throughout the world, including in the United States, the United Kingdom, elsewhere in Europe, India, Brazil, South Africa, Australia, and New Zealand.

Prescription trends

Between 1998 and 2017, along with amitriptyline, imipramine was the most commonly prescribed first antidepressant for children aged 5-11 years in England.

References

References

1. (28 August 2019). "Imipramine Use During Pregnancy".
2. Anvisa. (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial". [[Diário Oficial da União]].
3. (June 1979). "Bioavailability of imipramine tablets relative to a stable isotope-labeled internal standard: increasing the power of bioavailability tests". Journal of Pharmacokinetics and Biopharmaceutics.
4. (4 June 2013). "Product Information Tolerade (imipramine hydrochloride)". PMIP Pty Ltd.
5. (February 1991). "Behavioral, cognitive, and pharmacological treatments of panic disorder with agoraphobia: critique and synthesis". Journal of Consulting and Clinical Psychology.
6. (2005). "History repeats itself: pharmacodynamic trends in the treatment of anxiety disorders". Current Pharmaceutical Design.
7. (July 1999). "Imipramine treatment in pediatric burn patients with symptoms of acute stress disorder: a pilot study". Journal of the American Academy of Child and Adolescent Psychiatry.
8. (November 2005). "Early treatment of acute stress disorder in children with major burn injury". Pediatric Critical Care Medicine.
9. (November 2008). "Treating thermally injured children suffering symptoms of acute stress with imipramine and fluoxetine: a randomized, double-blind study". Burns.
10. (July 1996). "Platelet imipramine binding in patients with posttraumatic stress disorder before and after phenelzine treatment". Psychiatry Research.
11. (December 2019). "Pharmacological prevention and early treatment of post-traumatic stress disorder and acute stress disorder: a systematic review and meta-analysis". Translational Psychiatry.
12. (2020). "Antidepressants in Children and Adolescents: Meta-Review of Efficacy, Tolerability and Suicidality in Acute Treatment". Frontiers in Psychiatry.
13. (July 2013). "A systematic review of the efficacy and safety of desipramine for treating ADHD". Current Drug Safety.
14. (February 2005). "Are one or two dangerous? Tricyclic antidepressant exposure in toddlers". The Journal of Emergency Medicine.
15. (June 1982). "Imipramine and enuresis: never forget its dangers". Pediatrics.
16. (October 1995). "Therapeutic efficacy of antidepressants in agitated anxious depression--a meta-analysis of moclobemide studies". Journal of Affective Disorders.
17. (April 1974). "Imipramine, Sleep, And Enuresis". JAMA: The Journal of the American Medical Association.
18. (1994). "Imipramine and xylazine-induced ex copula ejaculation in stallions". Theriogenology.
19. (October 2001). "Oral imipramine and intravenous xylazine for pharmacologically-induced ex copula ejaculation in stallions". Animal Reproduction Science.
20. (September 1989). "Therapeutic monitoring of antidepressant drugs: guidelines updated". Therapeutic Drug Monitoring.
21. "Imipramine: MedlinePlus Drug Information".
22. "Imipramine Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD".
23. (2010). "Mosby's Nursing Drug Reference". Mosby Elsevier.
24. "PDSP ''K''_i Database". University of North Carolina at Chapel Hill and the United States National Institute of Mental Health.
25. "PDSP K_i Database". University of North Carolina at Chapel Hill and the United States National Institute of Mental Health.
26. (December 1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". European Journal of Pharmacology.
27. (December 1997). "Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites". The Journal of Pharmacology and Experimental Therapeutics.
28. (December 1986). "Antagonism by antidepressants of serotonin S1 and S2 receptors of normal human brain in vitro". European Journal of Pharmacology.
29. (2006). "Screening the receptorome yields validated molecular targets for drug discovery". Current Pharmaceutical Design.
30. (August 1996). "Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor". Psychopharmacology.
31. (March 1998). "Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications". NIDA Research Monograph.
32. (November 1989). "'[3H]quipazine' degradation products label 5-HT uptake sites". European Journal of Pharmacology.
33. (March 1993). "Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs". Molecular Pharmacology.
34. (August 1993). "Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype". The Journal of Biological Chemistry.
35. (August 1989). "The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action". European Journal of Pharmacology.
36. (December 1986). "Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative". Biochemical Pharmacology.
37. (August 1999). "Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding". Cellular and Molecular Neurobiology.
38. (December 2007). "Pharmacological properties of the active metabolites of the antidepressants desipramine and citalopram". European Journal of Pharmacology.
39. (May 1994). "Binding of antidepressants to human brain receptors: focus on newer generation compounds". Psychopharmacology.
40. (July 1984). "Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro". The Journal of Pharmacology and Experimental Therapeutics.
41. (February 2012). "Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics". Naunyn-Schmiedeberg's Archives of Pharmacology.
42. (June 1993). "Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics". Biochemical Pharmacology.
43. (March 2010). "Different interaction between tricyclic antidepressants and mecamylamine with the human alpha3beta4 nicotinic acetylcholine receptor ion channel". Neurochemistry International.
44. (November 1986). "1,3-Di(2-[5-3H]tolyl)guanidine: a selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs". Proceedings of the National Academy of Sciences of the United States of America.
45. (April 2010). "Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered". Human Psychopharmacology.
46. (April 2012). "Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo". European Neuropsychopharmacology.
47. (September 1999). "Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline". British Journal of Pharmacology.
48. [https://go.drugbank.com/salts/DBSALT000099 Imipramine hydrochloride. DrugBank Online]
49. (May 1991). "Dopamine D2 receptor blocking effect of imipramine in the rat hippocampus". Pharmacology, Biochemistry, and Behavior.
50. (August 2012). "Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys". Psychopharmacology.
51. (September 1988). "Muscarinic cholinergic receptor subtype on frog esophageal peptic cells: binding and secretion studies". The Journal of Pharmacology and Experimental Therapeutics.
52. (November 1975). "The use of bethanechol chloride with tricyclic antidepressants". The American Journal of Psychiatry.
53. (August 1993). "Treatment of nortriptyline's side effects in elderly patients: a double-blind study of bethanechol". The American Journal of Psychiatry.
54. (April 1986). "Bethanechol chloride can reverse erectile and ejaculatory dysfunction induced by tricyclic antidepressants and mazindol: case report". The Journal of Clinical Psychiatry.
55. (September 1987). "Reversal by bethanechol of imipramine-induced ejaculatory dysfunction". The American Journal of Psychiatry.
56. (December 2004). "Bethanecol chloride for treatment of clomipramine-induced orgasmic dysfunction in males". Revista do Hospital das Clinicas.
57. (April 2006). "Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action". Nature Neuroscience.
58. (October 2008). "The molecular neurobiology of depression". Nature.
59. (May 1990). "Clinical pharmacokinetics of imipramine and desipramine". Clinical Pharmacokinetics.
60. (15 February 2013). "Polypharmacy in Psychiatry Practice, Volume I: Multiple Medication Use Strategies". Springer Science & Business Media.
61. (2008). "Foye's Principles of Medicinal Chemistry". Lippincott Williams & Wilkins.
62. (20 September 1994). "Pharmacodynamics and Drug Development: Perspectives in Clinical Pharmacology". John Wiley & Sons.
63. (23 February 2012). "Metabolism of Drugs and Other Xenobiotics". John Wiley & Sons.
64. (2002). "Pharmacology Secrets". Elsevier Health Sciences.
65. (9 August 2012). "Shorter Oxford Textbook of Psychiatry". OUP Oxford.
66. (1987). "Antidepressant drugs: imipramine, mianserin and trazodone". Comparative Biochemistry and Physiology. C, Comparative Pharmacology and Toxicology.
67. (May 2001). "Pharmacotherapy of mental illness--a historical analysis". Progress in Neuro-Psychopharmacology & Biological Psychiatry.
68. (1999). "Synthesis of substituted 10,11-dihydro-5H-dibenz[b,f]azepines; key synthons in syntheses of pharmaceutically active compounds". Journal of Heterocyclic Chemistry.
69. (2012). "Trends and Changes in Drug Research and Development". Springer Science & Business Media.
70. (22 February 1991). "Histaminergic Neurons: Morphology and Function". CRC Press.
71. (21 April 2014). "History of the Synapse". CRC Press.
72. (2009). "Antidepressants". Infobase Publishing.
73. (2 January 2018). "Understanding Depression: Volume 2. Clinical Manifestations, Diagnosis and Treatment". Springer.
74. (October 2018). "The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?". Pharmacology & Therapeutics.
75. (April 2007). "Seminars in General Adult Psychiatry". RCPsych Publications.
76. (6 December 2012). "Forensic Toxicology: Controlled Substances and Dangerous Drugs". Springer Science & Business Media.
77. (1997). "The Antidepressant Era". Harvard University Press.
78. (1998). "Antidepressant-associated maniform states in acute treatment of patients with bipolar-I depression". European Archives of Psychiatry and Clinical Neuroscience.
79. (14 November 2014). "The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies". Springer.
80. (2000). "Index Nominum 2000: International Drug Directory". Taylor & Francis.
81. (6 December 2012). "Concise Dictionary of Pharmacological Agents: Properties and Synonyms". Springer Science & Business Media.
82. "Imipramine Uses, Side Effects & Warnings".
83. (2 April 2007). "Handbook of Essential Psychopharmacology". American Psychiatric Publishing.
84. (July 2020). "Incidence and prevalence of primary care antidepressant prescribing in children and young people in England, 1998-2017: A population-based cohort study". PLOS Medicine.